NCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
Eli Lilly and Company
Tianjin Medical University Cancer Institute and Hospital
Seagen Inc.
Bold Therapeutics, Inc.
J-Pharma Co., Ltd.
Sun Yat-sen University
TransThera Sciences (Nanjing), Inc.